Yarrow Bioscience secures $150M funding to advance first-in-class Graves' disease antibody into Phase II trials. Latest ...

NeuroHarmonics begins first patient trial of non-invasive deep-brain ultrasound for essential tremor. MHRA cleared. Learn ...

Johns Hopkins receives $2.5 million NIH grant to study TLR4's role in necrotizing enterocolitis. Discover breakthrough ...

FDA pushes zanzalintinib decision to March 2027. Exelixis' colorectal cancer drug review extended by 3 months. Latest updates ...

Navion Neurosciences secures $10.8M seed funding for precision sodium-channel medicines targeting genetic epilepsy and ...

Swedish Orphan Biovitrum receives FDA Fast Track Designation for pacritinib (Vonjo) treating VEXAS syndrome. Learn what this ...

Ethris GmbH secures €30M EIB financing for broad-spectrum nasal antiviral trials. mRNA respiratory treatment advances to ...

Third Arc Bio selects lead candidate for masked CD3 T cell engager under expanded Adagene collaboration. Milestone payments ...

CONNECTA Therapeutics secures €3.1M funding to advance CTH120, a TrkB modulator, into mid-stage trials for Fragile X syndrome ...

Gan & Lee Pharmaceuticals begins Phase I testing of GZC8072, a once-weekly oral GLP-1 peptide for type 2 diabetes and weight management. Learn more.

FDA places partial clinical hold on Biohaven's opakalim epilepsy drug. Impact on pivotal trial timeline and SK Biopharmaceuticals deal revealed.

NeOnc Technologies secures $15M funding to advance Phase II CNS cancer programs following NEO100 efficacy readout. Learn more ...